# US 11,027,155 B2 · Method for prevention and treatment of diabetic kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,155 B2
- Document ID: US11027155B2
- Status: Granted
- Kind: B2
- Application number: 16/653,665
- Filed: 2019-10-15
- Published: 2021-04-15
- Granted: 2021-06-08
- Earliest claimed: 2019-10-15
- Applicants: Guillermo Selman; Loay Hatem Salman
- Inventors: Guillermo Selman; Loay Hatem Salman
- Web page: https://patentgrep.com/patent/US11027155B2

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for delaying the progression or preventing Diabetic Kidney Disease by administering to a subject in need a composition containing a therapeutically effective amount of a hyaluronan synthesis inhibitor such as 4-Methylumbelliferone.

## Claims

### Claim 1

A method for delaying the progression of Diabetic Kidney Disease through the inhibition of hyaluronan synthesis in a subject in need thereof, wherein said method comprises the administration to said subject of a composition containing a therapeutically effective amount of at least one active agent from the Coumarin group (4-Methylumbelliferone, a 4-Methylumbelliferone metabolite, or a salt thereof) that reduces the amount of hyaluronans in diabetic kidneys.

### Claim 2 (depends on 1)

The method of claim 1, wherein the active agent in said composition is administered orally, or parenterally.